ArticleThe Journal of international medical research2025
A case of macular damage following micropulse laser treatment for central serous chorioretinopathy.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subthreshold micropulse laser treatment has proven to be an effective treatment for central serous chorioretinopathy. We report a rare case of localized macular damage following 577-nm subthreshold micropulse laser therapy in a patient with central serous chorioretinopathy in his early 40s, with 3-year longitudinal follow-up data. Pretreatment optical coherence tomography demonstrated the presence of subretinal hyperreflective material in the macular area. Despite adherence to validated fixed safety parameters during subthreshold micropulse laser application, post-treatment optical coherence tomography revealed partial macular damage characterized by disruption and atrophy of the ellipsoid and interdigitation zones. Fundus examination revealed localized lesions precisely corresponding to the subthreshold micropulse laser spot distribution patterns, confirming treatment-induced damage. These findings suggest that 577-nm subthreshold micropulse laser therapy for central serous chorioretinopathy induces macular damage, especially in patients with optical coherence tomography-detectable subretinal hyperreflective material. When subretinal hyperreflective material is present, careful energy adjustment is crucial. We recommend using reduced power settings (250-300 mW, 5% duty cycle) for subretinal hyperreflective material-associated central serous chorioretinopathy to enhance safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.